• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Accuray Incorporated filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    11/15/23 4:01:11 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care
    Get the next $ARAY alert in real time by email
    8-K
    0001138723false00011387232023-11-092023-11-09

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): November 9, 2023

    ACCURAY INCORPORATED

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-33301

    20-8370041

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    1240 Deming Way

     

    Madison, Wisconsin

     

    53717-1954

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 608 824-2800

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trading

    Symbol(s)

    Name of each exchange

    on which registered

    Common Stock, par value $0.001 per share

    ARAY

    The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    Amended and Restated 2016 Equity Incentive Plan

    At the Annual Meeting of Stockholders of Accuray Incorporated (the “Company”) held on November 9, 2023 (the “2023 Annual Meeting”), the Company’s stockholders approved amending and restating the Company’s 2016 Equity Incentive Plan to increase the number of shares of the Company’s common stock available for issuance thereunder by 5,000,000 shares. A description of the Amended and Restated 2016 Equity Incentive Plan is set forth in the Company’s definitive proxy statement on Form 14A filed with the United States Securities and Exchange Commission on September 29, 2023 and is qualified in its entirety by reference to the full text of the Amended and Restated 2016 Equity Incentive Plan, a copy of which is being filed as Exhibit 10.1 to this Form 8-K.

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

    At the 2023 Annual Meeting, the Company’s stockholders voted on five proposals as set forth below. The following is a brief description of each proposal submitted to a vote at the 2023 Annual Meeting, as well as the number of votes cast for and against, the number of abstentions, and the number of broker non-votes with respect to each proposal.

     

    Proposal No. 1: Election of Directors

     

    The stockholders elected each of the following persons as a Class II director of the Company to hold office until the Company’s 2026 Annual Meeting of Stockholders or until his or her successor is duly elected or appointed.

     

    Nominee

    For

    Against

    Abstain

    Broker Non-Votes

    Beverly A. Huss

    52,545,432

    2,250,590

    82,774

    21,979,065

    Mika Nishimura

    46,511,031

    8,206,385

    161,380

    21,979,065

    Byron C. Scott

    53,255,675

    1,540,693

    82,428

    21,979,065

     

    Proposal No. 2: Approval of Amendment to the Company’s 2016 Equity Incentive Plan

    The stockholders approved the Company’s Amended and Restated 2016 Equity Incentive Plan, with 47,745,958 shares in favor, 6,930,587 shares against, 202,251 shares abstaining and 21,979,065 broker non-votes.

    Proposal No. 3: Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers

     

    The stockholders cast an advisory vote to approve the compensation of the Company’s named executive officers as follows: 52,932,764 shares in favor, 1,806,228 shares against, 139,804 shares abstaining and 21,979,065 broker non-votes.

     

    Proposal No. 4: Advisory Vote on Frequency of Future Advisory Votes to Approve the Compensation of the Company’s Named Executive Officers

    The stockholders cast an advisory vote on the frequency of future advisory votes to approve the compensation of the Company’s named executive officers as follows: 53,206,233 shares in favor of one year, 68,767 shares in favor of two years, 1,462,873 shares in favor of three years, 140,923 shares abstaining and 21,979,065 broker non-votes.

    Considering the strong support for an annual vote as reflected in the voting results, the Company’s past practice of holding annual advisory votes and in light of Board’s recommendation of an annual frequency for future advisory votes to approve the compensation of the Company’s named executive officers, the Company will continue to hold future advisory votes to approve the compensation of the Company’s named executive officers annually until the matter is again submitted to the Company’s stockholders for a vote.

     

    Proposal No. 5: Ratification of Independent Registered Public Accounting Firm

     

    2

     


     

    The stockholders ratified the appointment of Grant Thornton LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2024, with 75,242,549 shares in favor, 1,332,584 shares against, 282,728 shares abstaining and no broker non-votes.

     

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit No. Description

    10.1 Accuray Incorporated Amended and Restated 2016 Equity Incentive Plan and forms of award agreements thereunder

    104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

    3

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ACCURAY INCORPORATED

     

    Dated: November 15, 2023

    By:

    /s/ Jesse Chew

    Jesse Chew

    Senior Vice President, Chief Legal Officer & Corporate Secretary

     

     

     

    4


    Get the next $ARAY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARAY

    DatePrice TargetRatingAnalyst
    2/13/2024$9.00Buy
    ROTH MKM
    6/23/2022$7.50Buy
    B. Riley Securities
    12/22/2021$7.50Buy
    Loop Capital
    More analyst ratings

    $ARAY
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Accuray Incorporated

    SCHEDULE 13G/A - ACCURAY INC (0001138723) (Subject)

    3/26/26 3:05:49 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray Incorporated filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - ACCURAY INC (0001138723) (Filer)

    3/19/26 4:01:54 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Accuray Incorporated

    EFFECT - ACCURAY INC (0001138723) (Filer)

    3/2/26 12:15:18 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Accuray Reports Fiscal 2026 Second Quarter Financial Results

    MADISON, Wis., Feb. 4, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the second quarter ended December 31, 2025. Key Highlights  On December 15, 2025 the Company announced the first phase of comprehensive, strategic, operational, and organizational transformational plan, which is expected to improve annualized operating profitability by approximately $25 million and set the stage for revenue growth:Plan includes organizational realignment, rightsizing of cost structure, outsourcing, and sales enablement in order to enhance competi

    2/4/26 4:05:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray to Report Second Quarter Fiscal 2026 Financial Results on February 4, 2026

    MADISON, Wis., Jan. 21, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the second quarter of fiscal year 2026, ended December 31, 2025, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on February 4, 2026. The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-855-669-9658 (USA) or 1-412-317-0088 (interna

    1/21/26 4:05:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray announces first phase of comprehensive strategic, operational, and organizational transformation plan; company expects first phase to improve annualized operating profitability by approximately $25 million and set the stage for renewed growth

    Plan includes organizational realignment, rightsizing of cost structure, outsourcing, and sales enablement in order to enhance competitiveness and support long-term strategy.Workforce optimization actions will affect approximately 15% of the company's employees.Of the expected $25 million of annualized operating profit improvement, approximately $12 million will be realized in FY2026.MADISON, Wis., Dec. 15, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today announced the first phase of its comprehensive strategic, operational, and organizational transformation plan. This phase is designed to realign its organization to produce sharper accountability, tighter cost control, and fast

    12/15/25 5:00:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chalke Sandeep

    4 - ACCURAY INC (0001138723) (Issuer)

    4/1/26 5:14:50 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    SVP, Chief Operations Officer Peralta Leonel converted options into 83,723 shares and covered exercise/tax liability with 28,969 shares (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    3/3/26 4:10:14 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Director Mayer Steven F bought $30,878 worth of shares (54,875 units at $0.56), increasing direct ownership by 4% to 1,545,620 units (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    2/23/26 4:10:08 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mayer Steven F bought $30,878 worth of shares (54,875 units at $0.56), increasing direct ownership by 4% to 1,545,620 units (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    2/23/26 4:10:08 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Director Mayer Steven F bought $103,797 worth of shares (195,125 units at $0.53), increasing direct ownership by 15% to 1,490,745 units (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    2/20/26 4:10:06 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    CEO La Neve Stephen R. bought $19,410 worth of shares (20,000 units at $0.97) (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    11/19/25 5:18:33 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Accuray with a new price target

    ROTH MKM initiated coverage of Accuray with a rating of Buy and set a new price target of $9.00

    2/13/24 6:29:42 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    B. Riley Securities initiated coverage on Accuray with a new price target

    B. Riley Securities initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50

    6/23/22 7:25:39 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Loop Capital initiated coverage on Accuray with a new price target

    Loop Capital initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50

    12/22/21 4:56:14 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Leadership Updates

    Live Leadership Updates

    View All

    Accuray Accelerates Transformation Efforts with Appointment of Experienced Executive Leaders to Drive Performance and Growth

    Industry Veteran Steve La Neve Named Chief Executive Officer Suzanne Winter to Retire as President and CEOCompany Appoints Steven F. Mayer as Transformation Board SponsorChan W. Galbato Nominated to Board of Directors MADISON, Wis., Oct. 20, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today announced it is engaging in a significant organizational, strategic, and operational transformation. To accelerate this work, the company's Board of Directors has appointed proven industry leaders with deep operational expertise to drive execution, strengthen performance, and enhance competitiveness. The transformation plan initiatives, most of which will be implemented during the current fisc

    10/20/25 9:20:00 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

    6/30/25 11:02:00 AM ET
    $ARAY
    $CLRB
    $ERAS
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Accuray Announces Convertible Notes Exchange and Refinancing of Existing Credit Facilities

    MADISON, Wis., June 6, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today announced that, after an extensive review over the last several months, including the evaluation of numerous potential financing partners, it has entered into privately negotiated agreements with the holders of its existing 3.75% senior convertible notes due 2026 (the "Notes") to exchange an aggregate of $82.0 million principal amount of Notes for an aggregate of 8,881,579 shares of the Accuray's common stock (the "Shares"). As part of the exchange consideration, Accuray will pay exchanging holders an aggregate of approximately $68.6 million in cash. The Exchange is expected to close on or about June 11, 202

    6/6/25 7:30:00 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Financials

    Live finance-specific insights

    View All

    Accuray Reports Fiscal 2026 Second Quarter Financial Results

    MADISON, Wis., Feb. 4, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the second quarter ended December 31, 2025. Key Highlights  On December 15, 2025 the Company announced the first phase of comprehensive, strategic, operational, and organizational transformational plan, which is expected to improve annualized operating profitability by approximately $25 million and set the stage for revenue growth:Plan includes organizational realignment, rightsizing of cost structure, outsourcing, and sales enablement in order to enhance competi

    2/4/26 4:05:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray to Report Second Quarter Fiscal 2026 Financial Results on February 4, 2026

    MADISON, Wis., Jan. 21, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the second quarter of fiscal year 2026, ended December 31, 2025, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on February 4, 2026. The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-855-669-9658 (USA) or 1-412-317-0088 (interna

    1/21/26 4:05:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray Reports Fiscal 2026 First Quarter Financial Results

    MADISON, Wis., Nov. 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the first quarter ended September 30, 2025. Key Highlights  On October 20, 2025, the Company announced accelerated transformation efforts, including:Appointed Steve La Neve as President and Chief Executive Officer. He succeeds Suzanne Winter, who will retire after six years of service and remain in an advisory role through the end of November 2025.Appointed Steven F. Mayer, a member of the Board of Directors, as the Transformation Board Sponsor to lead the Compan

    11/5/25 4:05:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Accuray Incorporated

    SC 13G/A - ACCURAY INC (0001138723) (Subject)

    9/6/24 9:00:07 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Accuray Incorporated

    SC 13G - ACCURAY INC (0001138723) (Subject)

    2/13/24 4:56:01 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Accuray Incorporated (Amendment)

    SC 13G/A - ACCURAY INC (0001138723) (Subject)

    2/13/24 11:19:22 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care